A New Startup Wants to Edit Human Embryos
For the first time since He Jiankui shocked the world seven years ago by revealing that he had created the first gene-edited babies, a new biotech startup is reviving the idea of editing human embryos to make disease-free children. Manhattan Genomics, based in New York, has announced plans to use advanced CRISPR technology to edit out genetic mutations that cause serious diseases such as Huntington's disease, cystic fibrosis, and sickle cell anemia.
The company aims to revolutionize medicine by making it possible to correct genetic mistakes at the embryo stage. Manhattan Genomics' goal is not to enhance human genes but to address inherited diseases. The startup has assembled a team of top scientists, including a prominent in vitro fertilization doctor, a data scientist, and two reproductive biologists.
Cathy Tie, one of the company's co-founders, sees this as a challenge she wants to take on when she saw it. She believes that human embryo editing should be more acceptable in society. However, experts warn that unintended "off-target" effects could occur if the technology is not precisely controlled. Moreover, there are concerns about eugenics and manipulation of human embryos.
The startup has received over 150 applications from qualified scientists within the first 24 hours of posting a role for a genome engineer. Manhattan Genomics' next step will be to study CRISPR in mice before moving on to monkeys, with human trials likely many years away due to regulatory obstacles.
While experts acknowledge that this technology is potentially powerful, they also express concerns about its use. Fyodor Urnov, a professor of molecular therapeutics at UC Berkeley, says he worries that the interest in gene editing for reproductive purposes might be driven by a "quasi-eugenics" mindset rather than a genuine desire to address genetic disease.
The Alliance for Regenerative Medicine and other organizations have called for a 10-year moratorium on heritable gene editing due to concerns about its risks. Manhattan Genomics' approach will need to meet the standards set forth in a report released last year by an international commission that recommended caution and incremental development of this technology.
For the first time since He Jiankui shocked the world seven years ago by revealing that he had created the first gene-edited babies, a new biotech startup is reviving the idea of editing human embryos to make disease-free children. Manhattan Genomics, based in New York, has announced plans to use advanced CRISPR technology to edit out genetic mutations that cause serious diseases such as Huntington's disease, cystic fibrosis, and sickle cell anemia.
The company aims to revolutionize medicine by making it possible to correct genetic mistakes at the embryo stage. Manhattan Genomics' goal is not to enhance human genes but to address inherited diseases. The startup has assembled a team of top scientists, including a prominent in vitro fertilization doctor, a data scientist, and two reproductive biologists.
Cathy Tie, one of the company's co-founders, sees this as a challenge she wants to take on when she saw it. She believes that human embryo editing should be more acceptable in society. However, experts warn that unintended "off-target" effects could occur if the technology is not precisely controlled. Moreover, there are concerns about eugenics and manipulation of human embryos.
The startup has received over 150 applications from qualified scientists within the first 24 hours of posting a role for a genome engineer. Manhattan Genomics' next step will be to study CRISPR in mice before moving on to monkeys, with human trials likely many years away due to regulatory obstacles.
While experts acknowledge that this technology is potentially powerful, they also express concerns about its use. Fyodor Urnov, a professor of molecular therapeutics at UC Berkeley, says he worries that the interest in gene editing for reproductive purposes might be driven by a "quasi-eugenics" mindset rather than a genuine desire to address genetic disease.
The Alliance for Regenerative Medicine and other organizations have called for a 10-year moratorium on heritable gene editing due to concerns about its risks. Manhattan Genomics' approach will need to meet the standards set forth in a report released last year by an international commission that recommended caution and incremental development of this technology.